2,2,2-trichloroethyl-4-oxopiperidine-1-carboxylate | 41979-38-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2,2,2-trichloroethyl-4-oxopiperidine-1-carboxylate
• 英文别名: 1-(2,2,2-Trichlor-carboethoxy)-4-piperidon；2,2,2-Trichloroethyl 4-oxopiperidine-1-carboxylate
• CAS: 41979-38-8
• 化学式: C₈H₁₀Cl₃NO₃
• 分子量: 274.531
• InChiKey: FPMKPDBDXSCMID-UHFFFAOYSA-N

物化性质

• 沸点：
  343.4±42.0 °C(Predicted)
• 密度：
  1.505±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2,2,2-trichloroethyl-4-oxopiperidine-1-carboxylate 在 四(三苯基膦)钯 、 sodium carbonate 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 生成
  参考文献：
  名称：

  Structure-based library design and the discovery of a potent and selective mast cell β-tryptase inhibitor as an oral therapeutic agent

  摘要：

  A solid phase combinatorial library was designed based on X-ray structures and in-silico models to explore an inducible S4+ pocket, which is formed by a simple side-chain rotation of Tyr95. This inducible S4+ pocket is unique to β-tryptase and does not exist for other trypsin-like serine proteases of interest. Therefore, inhibitors utilizing this pocket have inherent advantages for being selective against other proteases in the same family. A member of this library was found to be a potent and selective β-tryptase inhibitor with a suitable pharmacokinetic profile for further clinical evaluation.

  DOI：

  10.1016/j.bmcl.2011.11.119

文献信息

• Synthesis of 4-azepanones and heteroaromatic-fused azepines
  作者：Subas M. Sakya、Andrew C. Flick、Jotham W. Coe、David L. Gray、Sidney Liang、Fabiola Ferri、Michel Van Den Berg、Kees Pouwer

  DOI：10.1016/j.tetlet.2011.11.129

  日期：2012.2

  syntheses of versatile intermediate azepinones 2 and 3 are described. A 6-step intramolecular Dieckmann cyclization and decarboxylation led to the intermediate 3 while an alternate 4-step synthesis of 2 was developed and used for scale-up. The highlight of the second synthesis is the one-step per-bromination/elimination protocol from readily available azepinone 13a to provide a versatile scaffold in

  描述了通用中间体intermediate杂酮2和3的两种合成。6步分子内Dieckmann环化和脱羧反应生成中间体3，同时开发了2的交替4步合成方法，并用于规模放大。第二个合成的重点是易于获得的a庚酮13a的一步溴化/消除步骤，以提供乙烯基溴化物5中的多用途支架，从而能够在芳基部分周围形成SAR。还描述了中间体2向杂芳基a庚酮精细化的实例。
• [EN] NEW TETRACYCLIC COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS TÉTRACYCLIQUES
  申请人：MEDIVATION TECHNOLOGIES INC

  公开号：WO2009055828A1

  公开（公告）日：2009-04-30

  This disclosure relates to new tetracyclic compounds that may be used to modulate a histamine receptor in an individual. The compounds in one embodiment are tetracyclic [4,3- b]indoles. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

  这项披露涉及可能用于调节个体组织胺受体的新四环化合物。在一个实施例中，这些化合物是四环[4,3- b]吲哚类化合物。此外还提供了包含这些化合物的药物组合物，以及使用这些化合物进行各种治疗应用的方法，包括治疗认知障碍、精神障碍、神经递质介导的障碍和/或神经元障碍。
• Tetracyclic compounds
  申请人：HUNG David T.

  公开号：US20090239854A1

  公开（公告）日：2009-09-24

  This disclosure relates to new tetracyclic compounds that may be used to modulate a histamine receptor in an individual. The compounds in one embodiment are tetracyclic [4,3-b]indoles. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

  本公开涉及新的四环化合物，可用于调节个体中的组胺受体。在一种实施例中，该化合物为四环[4,3-b]吲哚。还提供了包含该化合物的药物组合物，以及使用该化合物进行各种治疗应用的方法，包括治疗认知障碍、精神障碍、神经递质介导的障碍和/或神经元障碍。
• TETRACYCLIC COMPOUNDS
  申请人：MEDIVATION TECHNOLOGIES, INC.

  公开号：US20140194414A1

  公开（公告）日：2014-07-10

  This disclosure relates to new tetracyclic compounds that may be used to modulate a histamine receptor in an individual. The compounds in one embodiment are tetracyclic[4,3-b]indoles. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

  本文涉及新的四环化合物，可用于调节个体中的组胺受体。在其中一种实施方式中，这些化合物是四环[4,3-b]吲哚。还提供了包含这些化合物的制药组合物，以及使用这些化合物进行各种治疗应用的方法，包括治疗认知障碍、精神障碍、神经递质介导的障碍和/或神经元障碍。
• Ring Cleavage Reaction of Heterocyclic Ketones Based on Crossed Aldol Condensation
  作者：Hiroshi Suemune、Jun Uchida、Kiyoshi Sakai

  DOI：10.3987/com-95-7339

  日期：——

  Ring cleavage reaction based on crossed aldol condensation using heterocyclic ketones such as 4-piperidone and nortropinone derivatives with benzaldehyde under acetalization conditions (BF3 . Et(2)O/ethylene glycol) has been achieved.